Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

391 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: results of a British Medical Research Council Multicenter Randomized Trial. Medical Research Council Lung Cancer Working Party.
Thatcher N, Girling DJ, Hopwood P, Sambrook RJ, Qian W, Stephens RJ. Thatcher N, et al. J Clin Oncol. 2000 Jan;18(2):395-404. doi: 10.1200/JCO.2000.18.2.395. J Clin Oncol. 2000. PMID: 10637255 Clinical Trial.
A randomised controlled trial of pre-operative chemotherapy followed, if feasible, by resection versus radiotherapy in patients with inoperable stage T3, N1, M0 or T1-3, N2, M0 non-small cell lung cancer.
Stephens RJ, Girling DJ, Hopwood P, Thatcher N; Medical Research Council Lung Cancer Working Party. Stephens RJ, et al. Among authors: thatcher n. Lung Cancer. 2005 Sep;49(3):395-400. doi: 10.1016/j.lungcan.2005.04.001. Lung Cancer. 2005. PMID: 15908042 Clinical Trial.
Ifosfamide, carboplatin, and etoposide with midcycle vincristine versus standard chemotherapy in patients with small-cell lung cancer and good performance status: clinical and quality-of-life results of the British Medical Research Council multicenter randomized LU21 trial.
Thatcher N, Qian W, Clark PI, Hopwood P, Sambrook RJ, Owens R, Stephens RJ, Girling DJ. Thatcher N, et al. J Clin Oncol. 2005 Nov 20;23(33):8371-9. doi: 10.1200/JCO.2004.00.9969. J Clin Oncol. 2005. PMID: 16293867 Clinical Trial.
The feasibility of using glycosylated recombinant human granulocyte colony-stimulating factor (G-CSF) to increase the planned dose intensity of doxorubicin, cyclophosphamide and etoposide (ACE) in the treatment of small cell lung cancer. Medical Research Council Lung Cancer Working Party.
Thatcher N, Anderson H, Bleehen NM, Girling DJ, Lallemand G, Machin D, Stephens RJ. Thatcher N, et al. Eur J Cancer. 1995;31A(2):152-6. doi: 10.1016/0959-8049(94)00416-3. Eur J Cancer. 1995. PMID: 7536433
Increasing and planned dose intensity of doxorubicin, cyclophosphamide and etoposide (ACE) by adding recombinant human methionyl granulocyte colony-stimulating factor (G-CSF; filgrastim) in the treatment of small cell lung cancer (SCLC). Medical Research Council Lung Cancer Working Party.
Thatcher N, Clark PI, Smith DB, Anderson H, Girling DJ, Machin D, Stephens RJ, Lallemand G, Jenkins B. Thatcher N, et al. Clin Oncol (R Coll Radiol). 1995;7(5):293-9. doi: 10.1016/s0936-6555(05)80536-9. Clin Oncol (R Coll Radiol). 1995. PMID: 8580054 Clinical Trial.
The strength of female sex as a prognostic factor in small-cell lung cancer: a pooled analysis of chemotherapy trials from the Manchester Lung Group and Medical Research Council Clinical Trials Unit.
Wheatley-Price P, Ma C, Ashcroft LF, Nankivell M, Stephens RJ, White SC, Lorigan P, Thatcher N, Blackhall FH, Shepherd FA. Wheatley-Price P, et al. Among authors: thatcher n. Ann Oncol. 2010 Feb;21(2):232-237. doi: 10.1093/annonc/mdp300. Epub 2009 Aug 12. Ann Oncol. 2010. PMID: 19675093 Free article.
391 results